Viridian unveiled successful across-the-board Phase III data on 16 December for veligrotug in chronic thyroid eye disease (TED), roughly three months after similar broad Phase III success with the candidate in active TED. Now, the company is planning to file a biologic licensing application at the US Food and Drug Administration in the second half of 2025 with hopes for a product launch in 2026.
Viridian Continues Building Case For Veligrotug In TED
Looking to compete with Amgen’s Tepezza, veligrotug has now met efficacy and safety endpoints in active and chronic patients, while offering less burdensome dosing.
More from Clinical Trials
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
More from Therapy Areas
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.